Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 25

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 25
---
 share equal to the closing price of an ordinary share on the Nasdaq Global Market on each purchase date. • Each of our executive officers received an annual cash bonus under our performance-based cash bonus program based on our achievement of 2024 corporate goals, which were intended to be motivational and more challenging than we expected to achieve. In 2025, after consulting with Mr. Winningham, our compensation committee did not award an annual replenishment equity grant to Mr. Winningham in order to reduce employee compensation costs. In addition, Mr. Winningham’s salary and target bonus were not increased for 2025. In accordance with Section 14A of the Exchange Act, we are asking shareholders to vote on the following resolution: “RESOLVED, as an ordinary resolution, that the compensation paid to the Company’s named executive officers as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion, is hereby approved.” An ordinary resolution, being a simple majority of the votes duly cast at the Annual Meeting, is required for the non-binding advisory resolution regarding the compensation of our named executive officers. Abstentions and broker non-votes will not affect the outcome of Proposal Three, other than counting towards the quorum of the meeting. This “Say On Pay” vote is advisory, and therefore not binding on our compensation committee or board of directors. Our board of directors and our compensation committee value the opinions of our shareholders, however, and will carefully review and consider the voting results when evaluating our executive compensation programs. We expect that our next shareholder vote on a “Say on Pay” Proposal will occur at our 2026 annual general meeting. OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” APPROVAL OF THE COMPENSATION OF THE COMPANY’S NAMED EXECUTIVE OFFICERS AS DISCLOSED PURSUANT TO ITEM 402 OF REGULATION S-K, INCLUDING THE COMPENSATION TABLES AND NARRATIVE DISCUSSION. 17 TABLE OF CONTENTS CORPORATE GOVERNANCE Code of Business Conduct Our board of directors has adopted a code of business conduct that applies to all of our employees, officers and directors, including our Chief Executive Officer, Chief Financial Officer, and other executive and senior financial officers. The full text of our code of business conduct is posted on the Investor Relations portion of our website at www.theravance.com. We intend to disclose future amendments to, or waiver of, our code of business conduct, at the same location